Evolution of cytogenetically normal acute myeloid leukemia during therapy and relapse: An exome sequencing study of 50 patients.

CONCLUSION: Chemotherapy resistance might be acquired through gain of mutations. Insights into the evolution during therapy and disease progression lay the foundation for tailored approaches to treat or prevent relapse of CN-AML.
PMID: 29330206 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 12, 2018 Category: Cancer & Oncology Authors: Greif PA, Hartmann L, Vosberg S, Stief S, Mattes R, Hellmann I, Metzeler KH, Herold T, Bamopoulos S, Kerbs P, Jurinovic V, Schumacher D, Pastore F, Bräundl K, Zellmeier E, Ksienzyk B, Konstandin N, Schneider S, Graf A, Krebs S, Blum H, Neumann M, Baldus Tags: Clin Cancer Res Source Type: research